JUDITH H. VEIS, M.D.; ROBERT CONTIGUGLIA, M.D.; MELVYN KLEIN, M.D.; JEFFREY MISHELL, M.D.; ALLEN C. ALFREY, M.D.; JOSEPH I. SHAPIRO, M.D.
To the editor: Deferoxamine has been increasingly used to treat iron and aluminum overload in uremic patients on dialysis. Because of the lack of renal function, the half-life of deferoxamine and its chelates, feroxamine and aluminoxamine, is markedly prolonged in this population (1). Although this action improves the effectiveness of chelation, toxicity could also be increased.
We recently saw fatal fungal infections in two nondiabetic patients among our patients on chronic dialysis who were receiving deferoxamine therapy. These patients had received deferoxamine for aluminum-associated bone disease for 4 months and 1 year, respectively. They were receiving a dose of 2
Learn more about subscription options.
Register Now for a free account.
VEIS JH, CONTIGUGLIA R, KLEIN M, MISHELL J, ALFREY AC, SHAPIRO JI. Mucormycosis in Deferoxamine-Treated Patients on Dialysis. Ann Intern Med. 1987;107:258. doi: 10.7326/0003-4819-107-2-258_1
Download citation file:
Published: Ann Intern Med. 1987;107(2):258.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only